Eli Lilly to acquire SiteOne Therapeutics

The latest stories trending on MedCity News.

Editor's Pick

Top Story Eli Lilly Commits $1B to Get Drug That Could Rival Vertex's New Non-Opioid Pain Med Eli Lilly's acquisition of SiteOne Therapeutics acquisition comes ahead of Phase 2 testing of the startup's lead drug candidate, which blocks the NaV1.8 sodium channel to treat pain. This target has clinical and regulatory validation from the recent FDA approval of Vertex Pharmaceuticals' pain drug, Journavx. Sponsored The Hidden Cost of Inaction Could Expose Preventable Risks Presented by Paubox A new report from Paubox reveals that email remains a major weak point in healthcare cybersecurity.  It also highlights that outdated legacy systems are especially vulnerable, lacking the speed and security required by today's healthcare environment. These vulnerabilities threaten patient care and organizational stability. Read the full report here.

Featured News

Death in Rocket Pharma Gene Therapy Study Puts Spotlight on Trial Change Intended to Improve Safety Rocket Pharmaceuticals adjusted the clinical trial design to include use of approved drug to avert an excessive immune response to its Danon disease gene therapy. The patient who died was one of two who received this drug under the revised protocol. Business Group on Health: Employers To Maintain Well-Being Benefits Despite Cost Challenges A new survey found that 73% of employers plan to maintain their well-being programs in 2025, while 20% will be expanding their programs. Menopausal Women Deserve Better Obesity Care Healthcare and benefits leaders must step up to provide menopausal women with the full-spectrum care they need to protect musculoskeletal and metabolic health for lifelong strength and well-being. When Medicaid Cost Cutting Is Simply Cost Shifting As speculation about whether Medicaid cuts will be part of the solution to our national debt problem continues, no one can predict how much the Medicaid rollback will be, or its impact on the one in five Americans who rely on it.

Video   What Will It Take to Fix Prior Authorization? Nowadays, there is much discussion about innovation and the role technology can play to improve the healthcare industry — but one expert is frustrated by the lack of movement in the prior authorization space. Jesse Ehrenfeld, immediate past president of the American Medical Association, pointed this out at MedCity News' INVEST conference in Chicago. The AMA has dedicated a lot of time and effort to working with payers and providers to establish a set of consensus guidelines for what the prior authorization process should look like — but payers aren't really coming to the table to make the necessary changes, Ehrenfeld said. "Got thrown out the window, completely ignored by the payer community," he stated.

Sponsored The Best Options for Diagnostic Imaging Covered by Medicare Presented by Envision Radiology Health care professionals can refer patients to the best options for diagnostic imaging covered by Medicare to give more people the medical assistance they need without extra financial stress. Learn More

Resources

MedCity News • PO Box 901 • New York, NY unsubscribe